Xention closes Series D financing - MarketLine Financial Deals

Xention closes Series D financing

Xention closes Series D financing - MarketLine Financial Deals
Xention closes Series D financing
Published Nov 23, 2010
4 pages — Published Nov 23, 2010
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Xention Limited, a UK-based biopharmaceutical company focused on the discovery and development of ion channel-modulating drugs, has secured GBP8 million in Series D financing led by new investor Seroba Kernel Life Sciences Limited.

  
Source:
Document ID
MA39848_101125
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Xention closes Series D financing" Nov 23, 2010. Alacra Store. Dec 10, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Xention-closes-Series-D-financing-2052-47827>
  
APA:
MarketLine Financial Deals. (2010). Xention closes Series D financing Nov 23, 2010. New York, NY: Alacra Store. Retrieved Dec 10, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Xention-closes-Series-D-financing-2052-47827>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.